DKCM
AXDX

Davidson Kempner Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

Davidson Kempner Capital Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25,200
Closed -$173K – 381
2022
Q4 		$173K Hold
25,200
– – ﹤0.01% 274
2022
Q3 		$383K Hold
25,200
– – 0.01% 326
2022
Q2 		$252K Buy
+25,200
New +$223K ﹤0.01% 338

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return

Davidson Kempner Capital Management's AXDX Position: Q1 2023 in Review

Davidson Kempner Capital Management sold out of Accelerate Diagnostics (AXDX) in Q1 2023, closing a stake of 25,200 shares — an estimated $173K sold.

Davidson Kempner Capital Management first reported a position in AXDX in Q2 2022 and held it in 3 quarters. The position peaked at $383K in Q3 2022. 67 funds tracked by Wall St. Rank hold AXDX as of Q1 2023.

  • Davidson Kempner Capital Management reported no remaining Accelerate Diagnostics position as of Q1 2023 after selling out during the quarter.
  • Davidson Kempner Capital Management sold 25,200 Accelerate Diagnostics shares in Q1 2023, an estimated $173K.
  • Davidson Kempner Capital Management first reported a position in Accelerate Diagnostics in Q2 2022 and held it in 3 quarters.
  • Davidson Kempner Capital Management's Accelerate Diagnostics position peaked at $383K in Q3 2022.
  • 67 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2023.

Based on Davidson Kempner Capital Management's 13F filing for Q1 2023, filed 15 May 2023.